Several phase I clinical trials of anti-MIF monoclonal antibody imalumab and anti-CD74 monoclonal antibody milatuzumab showed well-tolerance and efficacy in cancer (NCT01765790, NCT02540356 and NCT02448810), systemic lupus erythematosus (NCT01845740) and hematologic disorders (NCT01101594, NCT00603668 and NCT00989586). This evidence concerns the gene MIF and hematologic disorder.